Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

40.89 -1.73 (-4.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 Next >
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
Via MarketBeat
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
MarketBeat Week in Review – 2/26 - 3/1
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
Exposures Product Safety
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. 
Via MarketBeat
Exposures Product Safety
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
These 5 growth stocks are now in buy ranges
Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs. 
Via MarketBeat
Topics ETFs
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
Exposures Product Safety
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
Exposures Product Safety
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Why you can make Vertex Pharmaceuticals a buy on any pullback
Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely 
Via MarketBeat
Exposures COVID-19
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
3 Biotech Stocks to Buy for Long-Term Gains
The biotech sector is one of the most volatile sectors, but here are three biotech stocks that offer opportunities for patient biotech stock investors. 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Shares Higher On Optimism About CRISPR Partnership
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments. 
Via MarketBeat
Exposures Product Safety
No One Told These 3 Stocks It’s a Down Week
At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space. 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Electric Vehicles Interest Rates
MarketBeat: Week in Review 8/1 - 8/5
The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow. 
Via MarketBeat
Topics Economy Electric Vehicles
Exposures Electric Vehicles Interest Rates
Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment 
Via MarketBeat
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.